Skip to Content

Ceftriaxone Side Effects

Not all side effects for ceftriaxone may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to ceftriaxone: injection powder for solution

In addition to its needed effects, some unwanted effects may be caused by ceftriaxone. In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking ceftriaxone, check with your doctor or nurse immediately:

More common
  • Black, tarry stools
  • chest pain
  • chills
  • cough
  • fever
  • painful or difficult urination
  • shortness of breath
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen glands
  • unusual bleeding or bruising
  • unusual tiredness or weakness
Less common
  • Diarrhea
  • Abdominal or stomach cramps or tenderness
  • back, leg, or stomach pains
  • bleeding gums
  • bloating
  • blood in the urine or stools
  • bloody nose
  • bluish color
  • changes in skin color
  • clay-colored stools
  • convulsions
  • cough or hoarseness
  • dark urine
  • diarrhea, watery and severe, which may also be bloody
  • difficulty with breathing
  • difficulty with swallowing
  • dizziness
  • fast, irregular, pounding, or racing heartbeat or pulse
  • feeling of discomfort
  • feeling of warmth
  • fever with or without chills
  • general body swelling
  • general feeling of tiredness or weakness
  • headache
  • hives
  • increased sweating
  • increased thirst
  • inflammation of the joints
  • itching
  • loss of appetite
  • lower back or side pain
  • muscle aches
  • nausea or vomiting
  • noisy breathing
  • nosebleeds
  • pain
  • pale skin
  • pinpoint red spots on the skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rash
  • redness of the face, neck, arms, and occasionally, upper chest
  • shortness of breath
  • skin rash
  • swelling of the foot or leg
  • swollen lymph glands
  • tenderness
  • tightness in the chest
  • troubled breathing with exertion
  • unpleasant breath odor
  • unusual weight loss
  • vomiting of blood
  • watery or bloody diarrhea
  • wheezing
  • yellowing of the eyes or skin
Incidence not known
  • Blistering, peeling, or loosening of the skin
  • chest pain
  • coughing up blood
  • decrease in the amount of urine
  • excessive muscle tone
  • increased menstrual flow or vaginal bleeding
  • muscle stiffness, tension, or tightness
  • nosebleeds
  • paralysis
  • prolonged bleeding from cuts
  • red irritated eyes
  • red or black, tarry stools
  • red or dark brown urine
  • red skin lesions, often with a purple center
  • restlessness
  • skin rash with a general disease
  • swelling
  • trouble sitting still
  • unpleasant breath odor

Some of the side effects that can occur with ceftriaxone may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

  • Acid or sour stomach
  • belching
  • bloated
  • change in taste
  • dizziness
  • excess air or gas in the stomach or intestines
  • full feeling
  • headache
  • heartburn
  • indigestion
  • itching of the vagina or genital area
  • loss of taste
  • pain during sexual intercourse
  • passing gas
  • stomach discomfort, upset, or pain
  • thick, white vaginal discharge with no odor or with a mild odor
Incidence not known
  • Hives or welts
  • redness, swelling, or soreness of the tongue
  • swelling or inflammation of the mouth

For Healthcare Professionals

Applies to ceftriaxone: injectable powder for injection, intramuscular kit, intravenous solution


This drug was generally well tolerated. The most common side effects were eosinophilia, leukopenia, thrombocytopenia, diarrhea, rash, and increased hepatic enzymes. Incidence of side effects was somewhat higher in children and with higher doses.[Ref]


Very common (10% or more): Warmth/tightness/induration with IM injection (up to 17%)
Uncommon (0.1% to 1%): Injection site pain/discomfort, injection site induration, injection site tenderness, phlebitis after IV administration[Ref]

Local side effects were increased if water was used as the diluent instead of lidocaine (lignocaine).

IM injection has been associated with warmth, tightness, and induration in 17% of patients receiving the 350 mg/mL solution and 5% of patients receiving the 250 mg/mL solution.[Ref]


Common (1% to 10%): Eosinophilia, thrombocytosis, leukopenia, thrombocytopenia, neutropenia
Uncommon (0.1% to 1%): Anemia, granulocytopenia, coagulopathy, hemolytic anemia, lymphopenia, prolonged prothrombin time
Rare (less than 0.1%): Agranulocytosis, lymphocytosis, leukocytosis, monocytosis, basophilia, decreased prothrombin time, hemolysis (fatal)
Frequency not reported: Bleeding, hypoprothrombinemia
Postmarketing reports: Coombs' test false positive

Cephalosporin class:
-Frequency not reported: Aplastic anemia, hemorrhage, positive direct Coombs' test[Ref]

Nineteen cases (10 adults, 9 children) of immune hemolytic anemia have been reported, 9 of which were fatal. Symptoms occurred within minutes or weeks of drug administration. Initial symptoms included tachycardia, hypotension, dyspnea, pallor, back or leg pain, and decreased hemoglobin levels. Most of these patients had preexisting hematologic or immunodeficiency disorders, and 1 had Crohn's disease.

Bleeding and bruising (due to hypoprothrombinemia) may have been more prevalent in patients with liver or renal dysfunction, malnourished patients, patients with low vitamin K levels, and patients using this drug for a prolonged duration.

Hemolytic anemia and agranulocytosis have also been reported during postmarketing experience. Most cases of agranulocytosis (less than 500/mm3) were after 10 days of therapy and after total doses of at least 20 g.[Ref]


Shadows on sonograms of the gallbladder (mistaken for gallstones, but actually ceftriaxone-calcium precipitates) have been reported, primarily after doses higher than the standard recommended dose. Prospective studies showed variable incidence of precipitation with IV administration in children (more than 30% in some studies), but slow infusion (20 to 30 minutes) appeared to lower the incidence. Risk of forming precipitates was increased by duration of therapy exceeding 14 days, renal failure, dehydration, or total parenteral nutrition. Effect was usually asymptomatic, but clinical symptoms (e.g., pain, nausea, vomiting) have been reported. Precipitation was usually reversible upon drug discontinuation.

Both pseudocholelithiasis (biliary "sludging") and true cholelithiasis (ceftriaxone-containing gallstone) have been reported in association with doses greater than 2 g/day. A false-positive hepatobiliary scan occurred in a patient receiving this drug. A repeat test 2 weeks after this drug was discontinued was normal.

Hepatitis has also been reported during postmarketing experience.[Ref]

Common (1% to 10%): Increased hepatic enzymes, increased ALT, increased AST
Uncommon (0.1% to 1%): Increased bilirubin
Rare (less than 0.1%): Hepatitis, jaundice, gallbladder sludge, biliary lithiasis, cholestatic jaundice
Frequency not reported: Transient elevations in liver function tests, shadows on sonograms of the gallbladder, cholelithiasis, pseudocholelithiasis, false-positive hepatobiliary scan
Postmarketing reports: Gallbladder precipitation

Cephalosporin class:
-Frequency not reported: Hepatic dysfunction, cholestasis[Ref]


Common (1% to 10%): Diarrhea/loose stools
Uncommon (0.1% to 1%): Nausea, vomiting
Rare (less than 0.1%): Colitis, flatulence, dyspepsia, abdominal pain, pseudomembranous colitis
Frequency not reported: Clostridium difficile-associated diarrhea
Postmarketing reports: Pancreatitis, stomatitis, glossitis[Ref]

The onset of pseudomembranous colitis symptoms has been reported during or after antimicrobial treatment.[Ref]


A case of AGEP has been reported after administration of this drug. This was characterized by the appearance of an erythematous and generalized scarlatiniform rash with plaques covered by small nonfollicular pustules on the thighs, abdomen, and lower extremities. This drug was discontinued and the AGEP was completely resolved after 2 weeks.

Allergic dermatitis and urticaria have also been reported during postmarketing experience.

A case of occupational contact dermatitis has been reported in a nurse who prepared cephalosporin solutions for administration to patients. The dermatitis resolved after the nurse stopped preparing the solutions.[Ref]

Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Pruritus, maculopapular rash/exanthema, allergic dermatitis, diaphoresis
Rare (less than 0.1%): Urticaria
Frequency not reported: Severe dermatitis, exfoliative erythroderma, bruising
Postmarketing reports: Exanthema, severe cutaneous reactions, erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome/toxic epidermal necrolysis, acute generalized exanthematous pustulosis (AGEP)

Cephalosporin class:
-Frequency not reported: Contact dermatitis[Ref]


Common (1% to 10%): Increased BUN/serum urea
Uncommon (0.1% to 1%): Increased blood creatinine
Rare (less than 0.1%): Renal precipitations, nephrolithiasis, acute renal tubular necrosis
Postmarketing reports: Oliguria, ureteric obstruction, post-renal acute renal failure

Cephalosporin class:
-Frequency not reported: Renal dysfunction, toxic nephropathy[Ref]

Cases of renal precipitation have been reported, primarily in children older than 3 years who received either high daily doses (e.g., at least 80 mg/kg/day) or total doses exceeding 10 g and who had other risk factors (e.g., fluid restrictions, confinement to bed). Risk of forming precipitates was increased in immobilized or dehydrated patients. Precipitation was reversible upon drug discontinuation.

Renal precipitation has also been reported during postmarketing experience.[Ref]


Uncommon (0.1% to 1%): Genital fungal infection, urinary casts, candidiasis, vaginitis
Rare (less than 0.1%): Glycosuria, hematuria, crystalluria[Ref]


Severe and sometimes fatal reactions have been reported in term and premature newborns (younger than 28 days) treated with IV ceftriaxone and calcium-containing IV solutions; a crystalline material (ceftriaxone-calcium precipitate) has been observed in the lungs and kidneys at autopsy. The same IV infusion line was used for this drug and calcium-containing solutions in some cases; precipitate was observed in the IV infusion line in some cases. Ceftriaxone and calcium-containing solutions infused at different times by different IV lines resulted in at least 1 neonate fatality; there was no crystalline material observed at autopsy.

Edema has also been reported during postmarketing experience.[Ref]

Uncommon (0.1% to 1%): Pyrexia/fever, flushing
Rare (less than 0.1%): Edema, chills, drug fever, shivering
Postmarketing reports: Superinfection with nonsusceptible microorganisms, ceftriaxone-calcium precipitates/crystalline material

Cephalosporin class:
-Frequency not reported: Drug fever, superinfection[Ref]

Nervous system

Several cephalosporins have been implicated in triggering seizures, especially in patients with renal dysfunction when dose was not reduced.[Ref]

Uncommon (0.1% to 1%): Headache, dizziness, dysgeusia
Rare (less than 0.1%): Seizures
Postmarketing reports: Convulsion, vertigo, kernicterus

Cephalosporin class:
-Frequency not reported: Reversible hyperactivity, hypertonia, seizures triggered[Ref]


Uncommon (0.1% to 1%): Increased alkaline phosphatase
Postmarketing reports: Galactosemia test false positive, false-positive test for urinary glucose (nonenzymatic methods)

Cephalosporin class:
-Frequency not reported: Increased LDH, false-positive test for urinary glucose[Ref]


An allergic reaction manifested by itching, maculopapular rash, hyperthermia, flushing has been reported in a patient with X-linked agammaglobulinemia in the absence of IgE. T cell involvement was proposed as the mechanism.

Cross-sensitivity with other cephalosporins and penicillins has occurred; however, the incidence is unknown.[Ref]

Rare (less than 0.1%): Anaphylaxis/anaphylactic-type reactions (e.g., bronchospasms), serum sickness
Frequency not reported: Allergic reaction, cross-sensitivity
Postmarketing reports: Anaphylaxis (anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia), anaphylactic reaction, anaphylactoid reaction, hypersensitivity

Cephalosporin class:
-Frequency not reported: Allergic reactions, serum sickness-like reaction[Ref]


Rare (less than 0.1%): Palpitations
Frequency not reported: Thrombus[Ref]


Rare (less than 0.1%): Bronchospasm, epistaxis, allergic pneumonitis[Ref]


1. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories, Nutley, NJ.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

4. Pletz MW, Rau M, Bulitta J, et al. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Antimicrob Agents Chemother 48 (2004): 3765-72

5. Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D "Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease." N Engl J Med 337 (1997): 289-94

6. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS "Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents." Antimicrob Agents Chemother 40 (1996): 485-7

7. Nahata MC, Barson WJ "Ceftriaxone: a third-generation cephalosporin." Drug Intell Clin Pharm 19 (1985): 900-6

8. Rey D, Martin T, Albert A, Pasquali JL "Ceftriaxone-induced granulopenia related to a peculiar mechanism of granulopoiesis inhibition." Am J Med 87 (1989): 591-2

9. Duncan CJ, Evans TJ, Seaton RA "Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy." J Antimicrob Chemother 65 (2010): 2483-4

10. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with Lyme arthritis following treatment with ceftriaxone." Infection 24 (1996): 98-102

11. Fallon BA, Keilp JG, Corbera KM, et al. "A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy." Neurology (2007):

12. Nadelman RB, Arlin Z, Wormser GP "Life-threatening complications of empiric ceftriaxone therapy for seronegative Lyme disease." South Med J 84 (1991): 1263-5

13. Hull RL, Brandon D "Thrombocytopenia possibly caused by structurally related third-generation cephalosporins." Ann Pharmacother 25 (1991): 135-6

14. Valesova M, Mailer H, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with lyme arthritis following treatment with ceftriaxone." Infection 24 (1996): 98-102

15. "Hemolysis from Ceftriaxone." Med Lett Drugs Ther 44 (2002): 100-101

16. Baciewicz AM, Skiest DJ, Weinshel EL "Ceftriaxone-associated neutropenia." Drug Intell Clin Pharm 22 (1988): 826-7

17. Ramakrishnan K, Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42

18. Bickford CL, Spencer AP "Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature." Pharmacotherapy 25 (2005): 1389-95

19. Rivkin AM "Hepatocellular enzyme elevations in a patient receiving ceftriaxone." Am J Health Syst Pharm 62 (2005): 2006-2010

20. Simon N, Dussol B, Sampol E, et al. "Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients." Clin Pharmacokinet 45 (2006): 493-501

21. Eichmann A, Weidmann G, Havas L "One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin: a dose-range finding pilot study." Chemotherapy 27 (1981): 62-9

22. Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991): 1251-4

23. Arredondo JL, Diaz V, Gaitan H, Maradiegue E, Oyarzun E, Paz R, Reynal JL, Stamm W, Zambrano D "Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients." Clin Infect Dis 24 (1997): 170-8

24. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J "Ceftriaxone in the treatment of lyme neuroborreliosis." Infection 24 (1996): 88-90

25. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989): 165

26. Thomas P, Daly S, Misan G, Steele T "Comparison of the efficacy and adverse effect profile of cefotaxime and ceftriaxone in ICU patients with susceptible infections." Diagn Microbiol Infect Dis 15 (1992): 89-97

27. Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998): 662-3

28. Bailey RR, Walker RJ, Cook HB "Ceftriaxone-induced colitis." N Z Med J 98 (1985): 969

29. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801

30. Lopez AJ, O'Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991): 712-4

31. Moskovitz, BL "Clinical adverse effects during ceftriaxone therapy." Am J Med 77 (1984): 84-8

32. Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992): 329-30

33. Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988): 858

34. Grasberger H, Otto B, Loeschke K "Ceftriaxone-associated nephrolithiasis." Ann Pharmacother 34 (2000): 1076-7

35. Toll LL, Lee M, Sharifi R "Cefoxitin-induced interstitial nephritis." South Med J 80 (1987): 274-5

36. Gargollo PC, Barnewolt CE, Diamond DA "PEDIATRIC CEFTRIAXONE NEPHROLITHIASIS." J Urol 173 (2005): 577-578

37. Haskell RJ, Fujita NK, Stevenson JA, Border WA "Cefoxitin-induced interstitial nephritis." Arch Intern Med 141 (1981): 1557

38. Kudva-Patel V, White E, Karnani R, Collins MH, Assa'ad AH "Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia." J Allergy Clin Immunol 109(5 Pt 1) (2002): 888-9

39. Moallem HJ, Garratty G, Wakeham M, Dial S, Oligario A, Gondi A, Rao SP, Fikrig S "Ceftriaxone-related fatal hemolysis in an adolescent with perinatally acquired human immunodeficiency virus infection." J Pediatr 133 (1998): 279-81

40. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Contact Dermatitis 34 (1996): 226

41. Baniasadi S, Fahimi F, Mansouri D "Serum sickness-like reaction associated with cefuroxime and ceftriaxone." Ann Pharmacother 41 (2007):

42. Thiella G, Bucci L, Agrati AM, Palmieri G "Nonfatal anaphylactic shock following an unusual sensitization." J Occup Med 31 (1989): 490

43. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F, Perez E, Venuti A, Blanca M "Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses." J Allerg Clin Immunol 106 (2000): 1177-83

44. Lewis JD "Liquid sucralfate in the management of aphthous ulcers." Am Fam Physician 64 (2001): 737

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.